BACKGROUND: Vein wall fibrotic injury following deep venous thrombosis (VT) is associated with elevated matrix metalloproteinases (MMPs). Whether and by what mechanism MMP2 contributes to vein wall remodeling after VT is unknown. METHODS: Stasis VT was produced by ligation of the inferior vena cava and tissue was harvested at 2, 8, and 21 days in MMP2 -/- and genetic wild type (WT) mice. Tissue analysis by immunohistochemistry, enzyme-linked immunosorbent assay, real-time polymerase chain reaction, and zymography was performed. RESULTS: Thrombus resolution was less at 8 days in MMP2 -/- compared with WT, evidenced by a 51% increase in VT size (P < .01), and threefold fewer von Willebrand's factor positive channels (P < .05). In MMP2 -/- mice, the main phenotypic fibrotic differences occurred at 8 days post-VT, with significantly less vein wall collagen content (P = .013), fourfold lower procollagen III gene expression (P < .01), but no difference in procollagen I compared with WT. Decreased inflammation in MMP2 -/- vein walls was suggested by ∼ threefold reduced TNFα and IL-1β at 2 days and 8 days post-VT (P < .05). A fourfold increase in vein wall monocytes (P = .03) with threefold decreased apoptosis (P < .05), but no difference in cellular proliferation at 8 days was found in MMP2 -/- compared with WT. As increased compensatory MMP9 activity was observed in the MMP2 -/-mice, MMP2/9 double null mice had thrombus induced with VT harvest at 8 days. Consistently, twofold larger VT, a threefold decrease in vein wall collagen, and a threefold increase in monocytes were found (all P < .05). Similar findings were observed in MMP9 -/- mice administered an exogenous MMP2 inhibitor. CONCLUSIONS: In stasis VT, deletion of MMP2 was associated with less midterm vein wall fibrosis and inflammation, despite an increase in monocytes. Consideration that VT resolution was impaired with MMP2 (and MMP2/9) deletion suggests direct inhibition will likely also require anticoagulant therapy.
BACKGROUND: Vein wall fibrotic injury following deep venous thrombosis (VT) is associated with elevated matrix metalloproteinases (MMPs). Whether and by what mechanism MMP2 contributes to vein wall remodeling after VT is unknown. METHODS:Stasis VT was produced by ligation of the inferior vena cava and tissue was harvested at 2, 8, and 21 days in MMP2 -/- and genetic wild type (WT) mice. Tissue analysis by immunohistochemistry, enzyme-linked immunosorbent assay, real-time polymerase chain reaction, and zymography was performed. RESULTS:Thrombus resolution was less at 8 days in MMP2 -/- compared with WT, evidenced by a 51% increase in VT size (P < .01), and threefold fewer von Willebrand's factor positive channels (P < .05). In MMP2 -/- mice, the main phenotypic fibrotic differences occurred at 8 days post-VT, with significantly less vein wall collagen content (P = .013), fourfold lower procollagen III gene expression (P < .01), but no difference in procollagen I compared with WT. Decreased inflammation in MMP2 -/- vein walls was suggested by ∼ threefold reduced TNFα and IL-1β at 2 days and 8 days post-VT (P < .05). A fourfold increase in vein wall monocytes (P = .03) with threefold decreased apoptosis (P < .05), but no difference in cellular proliferation at 8 days was found in MMP2 -/- compared with WT. As increased compensatory MMP9 activity was observed in the MMP2 -/-mice, MMP2/9 double null mice had thrombus induced with VT harvest at 8 days. Consistently, twofold larger VT, a threefold decrease in vein wall collagen, and a threefold increase in monocytes were found (all P < .05). Similar findings were observed in MMP9 -/- mice administered an exogenous MMP2 inhibitor. CONCLUSIONS: In stasis VT, deletion of MMP2 was associated with less midterm vein wall fibrosis and inflammation, despite an increase in monocytes. Consideration that VT resolution was impaired with MMP2 (and MMP2/9) deletion suggests direct inhibition will likely also require anticoagulant therapy.
Authors: Leila Cuttle; Maria Nataatmadja; John F Fraser; Margit Kempf; Roy M Kimble; Mark T Hayes Journal: Wound Repair Regen Date: 2005 Mar-Apr Impact factor: 3.617
Authors: John J Bergan; Geert W Schmid-Schönbein; Philip D Coleridge Smith; Andrew N Nicolaides; Michel R Boisseau; Bo Eklof Journal: N Engl J Med Date: 2006-08-03 Impact factor: 91.245
Authors: Philip M Cummins; Nicholas von Offenberg Sweeney; Maria T Killeen; Yvonne A Birney; Eileen M Redmond; Paul A Cahill Journal: Am J Physiol Heart Circ Physiol Date: 2006-09-01 Impact factor: 4.733
Authors: Kristopher B Deatrick; Jonathan L Eliason; Erin M Lynch; Andrea J Moore; Nicholas A Dewyer; Manu R Varma; Charles G Pearce; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2005-07 Impact factor: 4.268
Authors: Peter K Henke; Charles G Pearce; Daria M Moaveni; Andrea J Moore; Erin M Lynch; Christopher Longo; Manu Varma; Nicholas A Dewyer; K Barry Deatrick; Gilbert R Upchurch; Thomas W Wakefield; Cory Hogaboam; Steven L Kunkel Journal: J Immunol Date: 2006-09-01 Impact factor: 5.422
Authors: Daniel D Myers; Peter K Henke; Patricia W Bedard; Shirley K Wrobleski; Neelu Kaila; Gray Shaw; Thomas R Meier; Angela E Hawley; Robert G Schaub; Thomas W Wakefield Journal: J Vasc Surg Date: 2006-09 Impact factor: 4.268
Authors: Daniel D Myers; Shirley K Wrobleski; Chris Longo; Patricia W Bedard; Neelu Kaila; George D Shaw; Frank J Londy; Suzan E Rohrer; Beverly A Fex; Paul J Zajkowski; Thomas R Meier; Angela E Hawley; Diana M Farris; Nicole E Ballard; Peter K Henke; Robert G Schaub; Thomas W Wakefield Journal: Thromb Haemost Date: 2007-03 Impact factor: 5.249
Authors: Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke Journal: J Surg Res Date: 2007-06-14 Impact factor: 2.192
Authors: Peter K Henke; Manu R Varma; Daria K Moaveni; Nicholas A Dewyer; Andrea J Moore; Erin M Lynch; Christopher Longo; C Barry Deatrick; Steven L Kunkel; Gilbert R Upchurch; Thomas W Wakefield Journal: Thromb Haemost Date: 2007-11 Impact factor: 5.249
Authors: Peter K Henke; Manu R Varma; K Barry Deatrick; Nicholas A Dewyer; Nicholas A Drewyer; Erin M Lynch; Andrea J Moore; Derek A Dubay; Pasu Sukheepod; Charles G Pearce; Gilbert R Upchurch; Steven L Kunkel; Michael G Franz; Thomas W Wakefield Journal: Thromb Haemost Date: 2006-02 Impact factor: 5.249
Authors: Nicholas A Dewyer; Osama M El-Sayed; Catherine E Luke; Megan Elfline; Nicolai Kittan; Ron Allen; Adriana Laser; Carson Oostra; Anthony Comerota; Cory Hogaboam; Steven L Kunkel; Peter K Henke Journal: Thromb Haemost Date: 2015-07-16 Impact factor: 5.249
Authors: Allan K Metz; Jose A Diaz; Andrea T Obi; Thomas W Wakefield; Daniel D Myers; Peter K Henke Journal: Methodist Debakey Cardiovasc J Date: 2018 Jul-Sep
Authors: Osama M El-Sayed; Nicholas A Dewyer; Catherine E Luke; Megan Elfline; Adriana Laser; Cory Hogaboam; Steven L Kunkel; Peter K Henke Journal: J Vasc Surg Date: 2015-10-23 Impact factor: 4.268
Authors: Andrea T Obi; Jose A Diaz; Nicole L Ballard-Lipka; Karen J Roelofs; Diana M Farris; Daniel A Lawrence; Peter K Henke; Thomas W Wakefield Journal: J Vasc Surg Venous Lymphat Disord Date: 2014-10-01
Authors: Christine Chabasse; Suzanne A Siefert; Mohammed Chaudry; Mark H Hoofnagle; Brajesh K Lal; Rajabrata Sarkar Journal: J Vasc Surg Venous Lymphat Disord Date: 2014-05-10
Authors: Stefano de Franciscis; Luca Gallelli; Bruno Amato; Lucia Butrico; Alessio Rossi; Gianluca Buffone; Francesco G Caliò; Giovanni De Caridi; Raffaele Grande; Raffaele Serra Journal: Int Wound J Date: 2015-09-24 Impact factor: 3.315
Authors: A T Obi; J A Diaz; N L Ballard-Lipka; K J Roelofs; D M Farris; D A Lawrence; T W Wakefield; P K Henke Journal: J Thromb Haemost Date: 2014-07-23 Impact factor: 5.824